Digest Network Come funziona
Network
/
Società
Zy
Non verificato

Zymeworks Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaMedicina Salute BenesserePubblico Esercizio/Vendita al dettaglio

36 comunicati stampa

Guarda tutti i comunicati
02/03/2026
Biotecnologia
Finanza
Medicina Salute Benessere
Management/Organizzazione Aziendale
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
27/01/2026
Biotecnologia
Zymeworks Announces Participation in Upcoming Investor Conferences
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotecnologia
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
11/01/2026
Biotecnologia
Medicina Salute Benessere
Pubblico Esercizio/Vendita al dettaglio
Annunci Economici
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
06/01/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Annunci Economici
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotecnologia
Medicina Salute Benessere
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnologia
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0
13/10/2025
Biotecnologia
Medicina Salute Benessere
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Fonte
Zymeworks Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0